|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistent with its role as tumor suppressor, we further find that the expression of the full-length BARD1 protein predicts outcome in colon cancer and that loss of full-length BARD1 protein is associated with a poor prognosis (P = 0.0002).
|
21693656 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the pattern of BARD1 isoform expression was similar in tumor and morphologically normal peri-tumor tissues, and only one novel isoform π was specifically upregulated in tumors.
|
21815143 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The BARD1 gene is mutated in a subset of breast and ovarian cancers, implicating BARD1 as a potential tumor suppressor.
|
15632137 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found BRCA1 localized in the cytoplasm with BARD1 in 51.4 % of tumors.
|
26395808 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The BRCA1 tumor suppressor and the BARD1 protein form a stable heterodimeric complex that can catalyze the formation of polyubiquitin chains.
|
15166217 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BRCA1 mRNA and protein in situ expression, as well as the amount of BRCA1 ligated to BARD1 in the tumor, lacked any associations with patient outcomes, likely due to high intratumoral heterogeneity, and thus could not be used for clinical purposes.
|
26490435 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
During this process, BRCA1-BARD1 facilitates the nucleolytic resection of DNA ends to generate a single-stranded template for the recruitment of another tumour suppressor complex, BRCA2-PALB2, and the recombinase RAD51.
|
28976962 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The BARD1/BRCA1 interaction is disrupted by BRCA1 missense mutations that segregate with breast cancer susceptibility, indicating that BARD1 may be involved in mediating tumour suppression by BRCA1.
|
8944023 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PALB2, RAD51C, and BARD1 are additional tumor suppressor genes which also mediate repair of double stranded DNA breaks through the HRD pathway and are implicated in hereditary breast (PALB2; BARD1) and ovarian (RAD51C) cancer.
|
30772928 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The breast- and ovarian-cancer-specific tumor suppressor BRCA1 and its heterodimeric partner BARD1 contain RING domains that implicate them as E3 ubiquitin ligases.
|
28564596 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BARD1 and BRCA1 form a stable heterodimer and dimerization, which is required for most tumor suppressor functions attributed to BRCA1.
|
17556008 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One particular protein, BARD1, seems to be an important regulator of the tumour-suppressor function of BRCA1, as well as acting as a tumour suppressor itself.
|
16633366 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BARD1 is required for protein stability and tumor suppressor functions of BRCA1, which depend on the ubiquitin ligase activity of the BRCA1-BARD1 heterodimer.
|
18089818 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BARD1 (BRCA1 associated RING domain protein 1), as an important animal tumor suppressor gene associated with many kinds of cancers, has been intensively studied for decades.
|
27502904 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression analysis using DNA microarrays classified the tumor as basal-like, with very low BARD1 and ID4 expression, but high expression of BRCA1, RAD51, PARP1, CHEK1, and FANCA.
|
20842729 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A tumor-associated mutation Q564H of BARD1 is defective in apoptosis induction, thus suggesting a role of BARD1 in tumor suppression by mediating the signaling from proapoptotic stress toward induction of apoptosis.
|
11779501 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, we have identified two potentially causative SNPs at the BARD1 locus associated with predisposition to high-risk neuroblastoma, and have shown that full-length BARD1 may act as tumor suppressor.
|
30132831 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TIEG in combination with Bard1 discriminated between N-/bad outcome from N-/good tumors with a sensitivity and specificity of 83 and 82%, respectively.
|
15218362 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BARD1, a tumor suppressor, is essential for genome stability by interaction with BRCA1.
|
31258718 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The BRCA1 tumor suppressor exists as a heterodimeric complex with BARD1, and this complex is thought to mediate many of the functions ascribed to BRCA1, including its role in tumor suppression.
|
17848578 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection.
|
30244837 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In breast cancer, BARD1 expression was correlated with poor differentiation and large tumor size, established factors of poor prognosis, as well as short disease-free survival.
|
16152612 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BRCA1-associated RING domain protein 1 (BARD1) is a tumor suppressor, which forms a heterodimer with BRCA1.
|
28161399 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Somatically acquired missense mutations were observed in one breast carcinoma and one endometrial tumor; in at least one of these cases, tumor formation was accompanied by loss of the wild-type BARD1 allele, following the paradigm for known tumor suppressor genes.
|
9425226 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BARD1 (BRCA1-associated RING-domain 1) is a tumor suppressor whose protein product interacts with BRCA1, and in which rare somatic and germline mutations have been reported in breast, uterine, and endometrial cancers.
|
16333312 |
2006 |